KR20080114286A - A novel process for preparing red ginseng and the composition comprising the same - Google Patents

Abstract

A process for preparing red ginseng and a composition comprising the same are provided to shorten the process time, to perform mass production, and to ensure excellent antioxidant effect by containing saponin Rg3, Rg5, Rk1, Rh1 and Rh2 which specifically exists in the red ginseng in a small amount. A process for preparing red ginseng comprises a first drying process for drying the washed 3-7 year old ginseng at 20-60 ‹C for 12-36 hours; a first steaming process for s steaming the ginseng at 95-155‹C under the pressure of 0.05 - 0.45MPa for 3-30 minutes; and a second drying process for drying the ginseng at 35-55‹C for 8-16 hours to be the moisture content of 14%.

Description

 A novel process for preparing red ginseng and the composition comprising the same}

       1 is a diagram showing the scavenging ability of the RGS of Comparative Example 1 to the peroxyl radical,

        2 is a diagram showing the scavenging ability of the NRGS of Example 2 for the peroxyl radical,

       3 is a diagram showing the scavenging ability of the peroxide nitrate of RGS of Comparative Example 1,

  4 is a diagram showing the scavenging ability of the NRGS of Example 2 with respect to the peroxide nitrate.

       The object of the present invention is superior to the conventional method for producing red ginseng, it is excellent in reducing the time and can be mass-produced, and contains not only a large amount of saponin Rg3, Rg5, Rk1, Rh1 and Rh2 which are present in specific amounts in red ginseng as well as excellent antioxidant. It is to provide a method for producing a novel red ginseng having an advantage that shows the effect and a composition comprising the same.

To capture the $ 3.5 billion global ginseng market, Korean bio venture companies are working hard to develop new global ginseng-related materials worth $ 3.5 billion annually. Until now, the only company that has standardized ginseng as a functional food and has been performing in the global market is the “Pharmton Company” under Beringer Ingelheim, Switzerland. National research on ginseng and commercialization of the venture industry are in progress.

Korean red ginseng has a historical record of about 1,000 years ago (there is a record of red ginseng in Goryeo-do, written by the Chinese Song Dynasty). have. In general, the numerical objectives of herbal medicines are known as: 1) reducing side effects such as toxicity, 2) altering herbal properties and enhancing drug efficacy, 3) improving storage and storage, and 4) correcting taste and odor and color. In general, red ginseng undergoes a second ingredient conversion during an appropriate heat treatment process, thereby generating new active ingredients unique to red ginseng or fresh ginseng, and some active ingredients increase in content. As such, new ingredients that do not exist in ginseng are produced according to the processing method of ginseng, and new processed ginsengs having better effects on various physiological activities including anticancer activity can be developed compared to ginseng (Okamura N. et al. , Biol . Pharm . Bull . , 17 (2) , p.270, 1994).

However, the manufacturing method of such red ginseng is washed with fresh ginseng as in Korean Patent Application Publication No. 1995-024707 (1995.09.15) and put in a steamer at 94-100 ° C, especially 96 ° C for 2-6 hours. Because steam is steamed, tissues may burst during the steaming process, and saponin, which is the main component of ginseng, escapes with water, causing loss of saponin.

On the other hand, Rg5, which is produced specifically by steaming, has an anti-anxiety effect (Cha HY et al., Biol Pharm Bull ., 28 (9) , pp1621-5, 2006), brain function improvement effect (Kang JS et al., Arch Pharm Res . , 28 (3) , pp335-342, 2005), antidiabetic effect (Kordella T et al., Diabetes Forecast , 57 (1) , pRG5-8, 2004), hepatitis C inhibitory effect (Neuberger J et al., The royal College of Physicians of London and the British Society of Gastroenterology., 49 , Suppl 1: I1-21, 2001), etc., Rg3 has an antistress effect (Chung BC et al., Pharmacol Res . , 54 (1) , pp46-9, 2006), anticancer effect (Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban , 37 (1) , pp 60-2, 2006), hepatoprotective effect (Kim DH et al., Biol Pharm Bull ., 28 (10) , pp 1992-4, 2005), antioxidant effect (Sun YX et al., J Agric Food Chem., 51 (9) , pp2555-8, 2003), angiogenesis inhibitory effect (Qui H et al., Zhonghua Wai Ke Za Zhi , 40 (8 ), pp606-8, 2002), vasorelaxation (Schini-Kerth VB et al., Eur J Pharmacol . , 367 (1) , pp51-7, 1999), platelet aggregation inhibitory activity (Lee HK et al., Biol Pharm Bull ., 21 (1) , pp79-80, 1998), etc. It is known to exhibit various physiological activities, such that red ginseng containing a large amount of saponin can expect various physiological activities as described above.

 Accordingly, the present inventors have developed a standardized method of producing red ginseng, which is excellent in time reduction effect and capable of mass production, compared to the existing red ginseng manufacturing method, and the red ginseng prepared by the manufacturing method of the present invention has been prepared in the existing method. In comparison, the present invention was completed by confirming that the red ginseng contained a large amount of Rg3, Rg5, Rk1, Rh1, and Rh2, and exhibited an excellent antioxidant effect.

The object of the present invention is superior to the conventional method for producing red ginseng, it is excellent in shortening time and can be mass-produced, and contains not only a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2 which are specifically present in red ginseng, but also excellent. The present invention provides a novel method for producing red ginseng having an antioxidant effect and a composition containing the same.

      In order to achieve the above object, the present invention is excellent in shortening the time through the process of drying, steaming and drying ginseng and mass production is possible, specifically present in red ginseng saponin Rg3, Rg5, Rk1, Rh1 And it provides a novel method for producing red ginseng having the advantage of not only contains a large amount of Rh2 but also exhibits an excellent antioxidant effect.

Hereinafter, the present invention will be described in detail.

Red ginseng of the present invention can be prepared as follows.

      After washing the ginseng 3 to 7 years, preferably 5 years old ginseng of the present invention, the first to dry 12 to 36 hours, preferably 20 to 28 hours at a temperature of 20 to 60 ℃, preferably 35 to 55 ℃ Drying process; 95 to 155 ° C, preferably 110 to 145 ° C, more preferably 116 under a pressure of 0.05 to 0.45 MPa, preferably 0.10 to 0.20 MPa, more preferably 0.10 to 0.14 MPa, except for the preheating time in a steamer A primary steaming step of steaming at a temperature of from 120 ° C. for 3 to 30 minutes, preferably 5 to 15 minutes, more preferably 8 to 12 minutes; A time period characterized in that it comprises a secondary drying step of drying at a temperature of 20 to 60 ° C., preferably 35 to 55 ° C., for 8 to 16 hours, preferably 10 to 14 hours, so that the moisture content is 14% or less Provides a method for producing red ginseng with excellent shortening effect and mass production, and containing a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2, which are specifically present in red ginseng, as well as showing excellent antioxidant effects. .

The ginseng used in the red ginseng manufacturing process is Korean ginseng ( Korea ginseng ; Panax ginseng CA Meyer , American ginseng ; Panax quinquefolium L. ), Sanchi ginseng ( Sanchi ginseng ; Panax notoginseng ( Burk .) FH Chen , Chikusetsu ginseng; Panax Japonicus CA Meyer ), Himalayan ginsneng ; Panax pseudo-ginseng Wall . subs . himalaicus Hara or Vietnamese ginseng; Panax vietnamesis Ha et Grushy ), preferably Korean ginseng ( Korea ginseng ; Panax ginseng CA Meyer or American ginseng ; Panax quinquefolium L. ) is characterized in that.

The red ginseng prepared by the above manufacturing method is dried through a common drying method such as shade drying or freeze drying, and then pulverized and powdered into fine particles, preferably a particle size of about 50 μm to 200 μm. It can be prepared in a composition such as pills, capsules, tablets using an excipient or carrier well known in the art.

Red ginseng prepared by the above method may be used as a raw material of various preparations by grinding into fine powder, preferably a powder of about 50 ~ 200㎛ size using a herbal medicine grinder.

In addition, the method for obtaining the extract of the red ginseng prepared by the above method will be described in detail. After grinding the red ginseng prepared by the above method, water of about 3 to 7 times the mass of the red ginseng, preferably about 4 to 6 times the mass After the addition, the mixture was allowed to stand at room temperature for about 3 to 7 hours, and then 0.5 to 2 liters of ethane was added, about 1 to 6 hours, preferably about 2 to 4 hours, about 1 to 6 times, preferably about 2 to 4 hours Extraction of red ginseng extract, cold needle extraction, reflux extraction or ultrasonic extraction, preferably reflux extraction, cooling the extracted solution to room temperature, filtering and removing ethanol using a reduced pressure concentrator of the red ginseng prepared by the method of the present invention Extracts can be obtained.

The production method of the present invention can be applied to ginseng leaves as well as ginseng itself. Although ginseng leaves have not been used for medicinal purposes, they have been discarded or used for feed, and some of them have been used as raw materials for cosmetics or foods. However, when ginseng leaf extracts are heated and pressurized in the same way as in the present invention, the medicinal effect is much better. Since it is fortified, it can be used for medicinal purposes through the preparation method of the present invention as well as for the use of ginseng leaves.

       Red ginseng prepared by the above method is characterized in that it enhances the content of the active ingredients that were present in trace amounts of existing ginseng or white ginseng, or conventional red ginseng.

       Red ginseng extract prepared by the production method of the present invention is characterized by exhibiting excellent antioxidant activity.

       The present invention provides a pharmaceutical composition for the prevention and treatment of oxidation-related diseases containing red ginseng or its extract as an active ingredient prepared from the production method and extraction method.

The pharmaceutical composition for preventing and treating oxidation-related diseases of the present invention comprises 0.1 to 50% by weight of the red ginseng or extract based on the total weight of the composition.

      Oxidation-related diseases as defined herein include obesity, aging, diabetes, arteriosclerosis, hyperlipidemia, kidney disease, gout, hypertension, liver disease, lung disease, hyperthyroidism, hypothyroidism, chronic fatigue syndrome, heart disease, stroke or neurodegenerative disease Diseases, preferably obesity, aging, diabetes, arteriosclerosis, hyperlipidemia, kidney disease or gout.

       The pharmaceutical composition comprising red ginseng of the present invention or extract thereof may further include appropriate carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

       The pharmaceutical dosage forms of the red ginseng and extracts thereof of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.

       Pharmaceutical compositions comprising red ginseng or extracts thereof according to the present invention, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Formulated in the form of can be used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, total

Powder, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and Mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

      Preferred dosages of the red ginseng of the present invention and extracts thereof vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.2 to 200 mg / kg, preferably 2 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

      The red ginseng of the present invention and extracts thereof may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

      Red ginseng and its extract prepared by the method of the present invention can be used as a raw material that is more potent than the original ginseng, that is, conventional ginseng has been used, that is, various pharmaceutical preparations, Chinese medicine, health food, food, tea, cosmetics, etc. have.

      Red ginseng of the present invention and extracts thereof have little toxicity and side effects, so can be used safely even for long-term administration for the purpose of prevention or treatment.

      The present invention provides a health functional food for the prevention and improvement of oxidation-related diseases containing red ginseng or its extract as an active ingredient prepared from the production method and the extraction method.

      The food to which the red ginseng and its extract may be added include, for example, various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules or beverages.

      It may also be added to food or beverages for the purpose of preventing oxidation-related diseases. At this time, the amount of the black ginseng and its extract in the food or beverage may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 5g, preferably 0.3 to 1g based on 100ml Can be added.

      The health functional beverage composition of the present invention is not particularly limited to other ingredients other than containing the red ginseng or red ginseng and extract thereof as essential ingredients in the indicated ratios, and additional ingredients such as various flavors or natural carbohydrates, such as ordinary drinks. It may contain as. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

      In addition to the red ginseng of the present invention and extracts thereof, various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

      Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

     However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Experimental Examples.

Comparative Example  1. Preparation of Jeonggwanjang Red Ginseng Extract

      After pulverizing 32.75 g of red ginseng jeonggwanjang, 1L of 80% ethanol was added and refluxed three times for 4 hours. The extracted solution was cooled to room temperature, filtered, and the solvent was removed using a vacuum condenser to obtain 9 g of red ginseng crude extract. 300 ml of water was added to the red ginseng crude extract and suspended. Then, 300 ml of ether was added to remove the nonpolar substance. 300 ml of saturated butanol was added to the remaining aqueous layer to extract saponin present in ginseng, and the butanol was removed using a vacuum concentrator. 1.25 g of red ginseng extract containing a large amount of ginseng saponin was obtained (hereinafter referred to as RGS), and used as a sample of the following experimental example.

Example  1. Preparation of Red Ginseng

Panax ginseng ( Panax ginseng) produced and distributed in Geumsan ginseng CA Meter ) After purchasing 2 kg, Korean ginseng was put in a screw washer and washed three times for 10 minutes, taking care not to peel off during the washing process, and the dried Korean ginseng was first dried at 40 ℃ for 24 hours. Place Korean ginseng dried at low temperature for 24 hours in a steamer, steam for 10 minutes at 118 ℃ under pressure (0.12MPa) except for preheating time, and then dry it for 2 hours at 50 ℃ for 12 hours to dry out. 475 g of red ginseng of the present invention was prepared (hereinafter referred to as HS).

Example  2. Preparation of Red Ginseng Extract

      Take 30.44 g of HS of Example 1, grind, add 1 L of 80% ethanol and reflux three times for 4 hours. The extracted solution was cooled to room temperature, filtered, and the solvent was removed using a vacuum condenser to extract red ginseng crude 8.4. g was obtained, and 300 ml of water was added to the crude red ginseng extract and suspended. Then, 300 ml of ether was added to remove the nonpolar substance. 300 ml of saturated butanol was added to the remaining aqueous layer to extract saponin present in Korean ginseng, and then butanol. Was removed by a vacuum condenser to obtain 1.14g of red ginseng extract containing a large amount of ginseng saponin (hereinafter referred to as NRGS), was used as a sample of the following experimental example.

Example  3. Preparation of Hwagi Red Ginseng

5 years old Korean ginseng 2kg 6 years old ginseng ( Panax) in Example 1 quinquefolium L. ) 50g of Hwagi red ginseng of the present invention was prepared by following the same procedure except changing to 50g (hereinafter, referred to as WGHS).

Example  4. Preparation of Hwagi Red Ginseng Extract

      Except for changing the HS.30.44g of Example 1 in Example 2 to 50g of WGHS in Example 3 to obtain 4.82g Hwagi red ginseng extract (hereinafter referred to as WGRGS), the sample of the following Experimental Example Used.

Experimental Example  1. Red Ginseng Saponin Analysis

 In order to analyze the components of ginseng saponin present in the red ginseng extract, 20 mg of RGS of Comparative Example 1, NRGS of Example 2 or WGRGS of Example 4 was dissolved in 1 ml of methanol, and the filtrate was filtered with a 0.45 μm filter. The components were analyzed by HPLC analysis conditions of 1, and the results are shown in Table 2 below.

column Shiseido C18 column (5㎛, 1504.6mm) flux 1ml / min Detector ELSD-LT Detector menstruum A; CH ₃ CN: H ₂ O: 5% CH ₃ COOH = 15: 80: 5, B; CH ₃ CN: H ₂ O = 80: 20 0 min (0% B), 0-10 min (30% B), 10-25 min (50% B), 25-40 (100% B), 40- 50 minutes (100% B), 50-55 minutes (0% B), 55-58 minutes (0% B) Temperature 40 ℃

RGS (%) of Comparative Example 1 NRGS (%) of Example 2 WGRGS (%) of Example 4 Rb1 0.491 0.415 2.161 Rb2 0.253 0.205 0.096 Rc 0.225 0.229 0.282 Rd 0.104 0.096 0.454 Re 0.272 0.221 0.987 Rg1 0.363 0.318 0.241 Rg2 0.042 0.049 0.042 Rg3 0.061 0.102 0.212 Rh1 0.053 0.086 0.064 Rh2 0.042 0.072 0.12 Rk1 + Rg5 0.053 0.128 0.212 Sum 1.959 1.921 4.871

      As a result, as shown in Table 2, the NRGS of Example 2 was increased by about 1.7 times as compared to the Rg3 content of the RGS of Comparative Example 1 was 0.061% to 0.102% Rg3 content. In addition, the NRGS of Example 2 had an Rk1 + Rg5 content of 0.128%, which was more than two times higher than the RK1 + RG5 content of RGS of Comparative Example 1, which was 0.053%, and in the case of Rh1 and Rh2. It can be observed that the NRGS of 2 increased about 1.7 times as compared to the RGS of Comparative Example 1. In addition, the WGRGS of Example 4 was increased by about 3.5 times compared to the RGS of Comparative Example 1 with an Rg3 content of 0.212%, and increased by about 4 times compared with the RGS of Comparative Example 1 with RK1 + Rg5 content of 0.212%. , Rh1 increased about 1.2 times, and Rh2 increased about 3 times.

From this, the red ginseng prepared by the preparation method of the present invention and its extracts were found to contain a large amount of saponins Rg3, Rk1, Rg5, Rh1 and Rh2 present in trace amounts in the existing red ginseng.

Experimental Example 2. Oxy radical scavenging activity

TOSC (Total Oxy Radical Scavenging Activity ) Assay (Winston et al., Free Radic Biol Med., Feb, 24 (3), to determine the antioxidant effect by measuring the radical scavenging ability of NRGS of Example 2 or WGRGS of Example 4 , pp480-493, 1998; Regoli and Winston, Toxicol Appl Pharmacol., Apr 15, 156 (2) , pp96-105, 1999).

       20 mM concentration of ABAP (2,2'-azobisamidinopropane, Sigma) spontaneously decomposed at 35 ° C. to generate peroxyl radicals and spontaneous decay of 70 microM SIN-1 (Sigma) Peroxynitrate was generated, and the peroxy radical and peroxide nitrate generated were reacted with KMBA (α-keto-γ-metholbutyric acid, Sigma) present in 0.2 mM concentration in the reaction solution to generate ethylene gas. The oxyradical scavenging ability was measured by confirming whether ethylene gas was detected by the reaction with RGS of Example 1, NRGS of Example 2 or WGRGS of Example 4.

     RGS of Comparative Example 1, NRGS of Example 2 or WGRGS of Example 4 were diluted with water to a concentration of 0.0125, 0.025, 0.05 or 0.1 mg / ml to a final volume of 1 ml and then rubber septum It was placed in a sealed 10 ml vessel with a rubber septum, and 200 microL of air in the head space of the reaction vessel was taken, and the head-space technique was used for gas chromatography (GC) under the conditions shown in Table 3 below. 150 μl of air in the vial was taken with a gas-tight syringe to inject the gas-tight syringe into the injector to quantify the ethylene gas of the vial. ), The TOSC value was obtained from Equation 1 below using the graph (see FIGS. 1 to 4), and the results are shown in Tables 4 and 5 below.

Column  Poropack N column Detector  Flame ionizing detector (FID)  Temperature  Oven 60 ℃, Injector 180 ℃, Detector 180 ℃ Flow rate  30 mL / min Injection volume  20 μl Mobile phase  helium

TOSC = 100-(∫SA / ∫CA × 100)

∫SA = range integrated from the curve of the sample response

∫CA = integrated range from curve of control response

Scavenging ability against peroxyl radical Test group TOSC value Specific TOSC Value (TOSC / mg) RGS of Comparative Example 1 Concentration (mg / ml) 0.0125 0.025 0.05 0.1 377 ± 14 TOSC value 4.0 11.2 19.8 37.6 NRGS of Example 2 Concentration (mM) 0.0125 0.025 0.05 0.1 423 ± 4 TOSC value 5.8 10.6 21.6 42.4 WGRGS of Example 4 Concentration (mM) 0.0125 0.025 0.05 0.1 390 ± 26 TOSC value 5.1 12.8 23.1 39.0

Scavenging ability against peroxide Test group TOSC value Specific TOSC Value (TOSC / mg) RGS of Comparative Example 1 Concentration (mg / ml) 0.0125 0.025 0.05 0.1 336 ± 8 TOSC value 3.7 9.2 17.5 34.4 NRGS of Example 2 Concentration (mM) 0.0125 0.025 0.05 0.1 379 ± 10 TOSC value 5.7 11.1 20.5 38.3 WGRGS of Example 4 Concentration (mM) 0.0125 0.025 0.05 0.1 360 ± 25 TOSC value 6.1 13.7 19.9 37.2

      As a result, as shown in Table 4 and Table 5, the NRGS of Example 2 has a specific TOSC value of 423 ± 4 TOSC / mg for peroxyl radicals, and the RGS of Example 1 is 377 ± 14. About 46 TOSC / mg was higher compared to TOSC / mg, WGRGS of Example 4 had a TOSC value of 390 ± 26 TOSC / mg, which was about 13 TOSC / mg higher than the RGS of Comparative Example 1 The NRGS of Example 2 had a specific TOSC value of 379 ± 10 TOSC / mg for peroxynitrite, which was about 43 TOSC / mg higher than the RGS of Comparative Example 1, which was 336 ± 8 TOSC / mg, WGRGS of Example 4 had a TOSC value of 360 ± 25, which was about 24 TOSC / mg higher than that of RGS of Comparative Example 1. From this, the extract of red ginseng or red ginseng of the present invention contained peroxyl radical and peroxide nitrate It has high antioxidant activity against, and shows much better antioxidant activity compared to red ginseng prepared by conventional manufacturing methods. I could see the smell.

Experimental Example 3. Acute Toxicity Test

      Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals in each group were orally administered NGRS of Example 2 or WGRGS of Example 4 at a dose of 1 g / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, no clinical symptoms or dead animals were observed in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. As a result, the extract of the present invention did not show a change in toxicity even in rats up to 1 g / kg, respectively, the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of more than 1 g / kg.

      Hereinafter, the preparation examples of the composition comprising the red ginseng or extract, but this is not intended to limit the present invention only intended to be described in detail.

Formulation Example 1 Preparation of Powder

HS 20 mg of Example 1

Lactose 100 mg

Talc 10 mg

      The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

10 mg of WGHS of Example 3

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

      After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation example  3. Manufacture of capsule

10 mg of NRGS of Example 2

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

      According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

10 mg of WGRGS of Example 4

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

_{Na 2 HPO 4 · 12H 2 O} 26 mg

      According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation example  5. Liquid  Produce

20 mg of NRGS of Example 2

10 g of isomerized sugar

5 g of mannitol

Purified water

      According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added to the mixture, and then the above ingredients are mixed, purified water is added to adjust the total amount to 100 ml, and then filled in a brown bottle. The solution is prepared by sterilization.

Formulation example  6. Manufacture of healthy food

HS 1000 mg of Example 1

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

      Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation example  7. Manufacture of health drinks

WGRGS 100 mg of Example 4

15 g of vitamin C

100 g of vitamin E (powder)

Iron lactate 19.75 g

3.5 g of zinc oxide

Nicotinamide 3.5 g

0.2 g of vitamin A

0.25 g of vitamin B ₁

0.3 g of vitamin B ₂

Water quantification

       After mixing the above components in accordance with the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.

Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

      As described above, the present invention is superior to the conventional red ginseng manufacturing method, the time-saving effect is excellent and can be mass-produced, and contains a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2 which are present in specific amounts in red ginseng. As well as a novel method for producing red ginseng having the advantages of showing an excellent antioxidant effect and a composition containing the same.

Claims (9)

      After washing 3 to 7 years old ginseng, the first drying step of drying for 12 to 36 hours at a temperature of 20 to 60 ℃; A primary steaming step of steaming at a temperature of 95 to 155 ° C. under a pressure of 0.05 to 0.45 MPa except for a preheating time in a steamer; It is excellent in shortening time, mass production is possible, and it is characterized by including a secondary drying process for drying the water content to 14% or less for 8 to 16 hours at a temperature of 35 to 55 ℃, specifically for red ginseng A method for producing red ginseng having the advantage of containing a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2 present in trace amounts. According to claim 1, wherein the ginseng is Korea ginseng ( Korea ginseng ; Panax ginseng CA Meyer , American ginseng ; Panax quinquefolium L. ), Sanchi ginseng; Panax notoginseng ( Burk .) FH Chen , Chikusetsu ginseng ; Panax Japonicus CA Meyer ), Himalayan ginsneng ; Panax pseudo-ginseng Wall . subs . himalaicus Hara) of ginseng or Vietnamese (Vietnamese ginseng ; Panax vietnamesis Ha et Grushy ) Red ginseng characterized in that the manufacturing method.       The method according to claim 1, wherein the first steaming process is performed at 110 to 145 ° C. for 5 to 15 minutes under a pressure of 0.10 to 0.20 MPa.        The method according to claim 3, wherein in the first steaming process, steaming is performed at 116 to 120 ° C. for 8 to 12 minutes under a pressure of 0.10 to 0.14 MPa. Red ginseng prepared by the method of claim 1 is pulverized, and 3 to 7 times the mass of water is added thereto and left for 3 to 7 hours, and a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof is extracted. A method for obtaining an extract of red ginseng using as a solvent.        A pharmaceutical composition for the prevention and treatment of oxidation-related diseases, comprising as an active ingredient red ginseng obtained by the method of claim 1 or red ginseng obtained by the method of claim 5.        According to claim 6, The oxidation-related diseases are obesity, aging, diabetes, arteriosclerosis, hyperlipidemia, kidney disease, gout, hypertension, liver disease, lung disease, hyperthyroidism, hypothyroidism, chronic fatigue syndrome, heart disease, Pharmaceutical composition, characterized in that it is a stroke or neurodegenerative disease. A health functional food for the prevention and improvement of oxidation-related diseases containing red ginseng obtained by the method of claim 1 or red ginseng obtained by the method of claim 5 as an active ingredient.        The dietary supplement of claim 8 which is a powder, granule, tablet, capsule, syrup or beverage.

Images